The main clinical and immunological aspects of post-COVID syndrome


  • Natalia Makienko Mechnikov Institute of Microbiology and Immunology of the National Academy of Medical Sciences of Ukraine , Ukraine
  • Valery Minukhin Mechnikov Institute of Microbiology and Immunology of the National Academy of Medical Sciences of Ukraine , Ukraine
  • Tetyana Kolyada Mechnikov Institute of Microbiology and Immunology of the National Academy of Medical Sciences of Ukraine , Ukraine
  • Inna Toryanyk Mechnikov Institute of Microbiology and Immunology of the National Academy of Medical Sciences of Ukraine , Ukraine
  • anatoly Sklyar Mechnikov Institute of Microbiology and Immunology of the National Academy of Medical Sciences of Ukraine , Ukraine



COVID-19 pandemic has encouraged many researchers to focus on the formation of further changes in the human body caused by SARS-CoV-2, as well as to study the epidemiological, pathophysiological and immunological processes of coronavirus disease in the long term in order to determine the therapeutic tactics of patients. The article presents the main overview provisions of the formation of post- Covid-19 syndrome in individuals who have been infected with SARS-CoV-2. The reasons, symptoms and the most common syndromes that occur in patients after suffering a coronavirus infection are also given. Scientific data obtained over the past months confirm that individuals after an infection show a clear relationship between the primary severity of the course and various reactions of immune system, changes in laboratory parameters to viral load in the remote period. The obtained research results indicate various immune reactions and basic syndromes that can persist for a long time, which, according to the authors, is associated not only with the presence of comorbid conditions in the patient, but also with the activation of endogenous viruses or an imbalance in the intestinal microbiota.

Keywords: post- COVID -19 syndrome, clinical and immunological changes



COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE guideline. Published. 18 December 2020.

Coronavirus disease (COVID-19) Weekly Epidemiological Update of World Health Organization. 2020. cited 2020 Aug 20.

Centers for Disease Control and Prevention. COVID Data Tracker. Published 2021.

Chopyak V.V., Lischuk-Yakimovych H.O., Pukalyak R.M. Immunological aspects of COVID-2019: realities and prospects. (2020). Immunology and Allergy Science and Practice.

Logue J.K. , Franko N.M., McCulloch D. J. et al. (2021). Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA. Netw Open. Vol.4(2). e210830. 10.1001/jamanetworkopen.2021.0830.

Golubovska O.A. (2021). Post-COVID-19 syndrome: pathogenesis and main areas of rehabilitation. Health of Ukraine. № 2 (495). P. 16-18.

Garg P., Arora U., Kumar A., Wig N. (2021). The “post-COVID” syndrome: How deep is the damage? Journal of Medical Virology. Vol.93 (2). P.673-674. 10.1002/jmv.26465

Carfì A., Bernabei R., Landi F. (2020). Persistent symptoms in patients after acute COVID-19. Jama. Vol.324 (6).P. 603-605. 10.1001/jama.2020.12603

Al-Jahdhami I., Al-Naamani K., Al-Mawali A. (2021). The Post-acute COVID-19 Syndrome (Long COVID). Oman Med. J. 36.- e220. https:// 10.5001/omj.2021.91

Jake S. O’Donnell, Keith J. Chappell. Chronic SARS-CoV-2, a Cause of Post-acute COVID-19 Sequelae (Long-COVID)? HYPOTHESIS AND THEORY. Front. Microbiol. 02 August 2021

Proal Amy D. and VanElzakker Michael B. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. (2021) Front. Microbiol. 23 June

Komaroff A. The tragedy of the post-COVID “long haulers”.

Varga Z., Flammer A.J., Steiger P. et al. (2020). Endothelial cell infection and endotheliitis in COVID-19. The Lancet. Vol.395 (2). P. 1417-1418. (20)30937-5.

Levison M.E. Commentary: what we know so far about post-COVID syndrome.

Terpos E., Ntanasis-Stathopoulos I., Elalamy I., et al. (2020). Hematological findings and complications of COVID-19. Am J Hematol. Vol. 95 (7). P.834-847.

Ferrario C., Jessup J., Chappell M. et al. (2005). Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation.Vol. 111.P.2605-2610.

Mandal S., Barnett J., Brill S.E. et al. (2020). ARC Study Group. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalization for COVID-19. Thorax. Vol. 76 (4). P.396-398 818

Leisman DE, Deutschman CS, Legrand M. (2020) Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med. Vol. 46. P. 1105–1108.

Lucas C, Wong P, Klein J, et al. (2020). Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature .Vol. 584.P. 463–469.

Rupprecht TA, Koedel U, Angele B, Fingerle V, Pfister HW (2006) [Cytokine CXCL13: a possible early CSF marker for neuroborreliosis.]. Nervenarzt. Vol.77. P.470–473.

Rydkina E, Turpin LC, Sahni SK. (2010) Rickettsia rickettsii infection of human macrovascular and microvascular endothelial cells reveals activation of both common and cell type-specific host response mechanisms. Infect Immun.Vol.78.P.2599–25606.

Waldman B S, Schwarz Dominic, Wadsworth Marc H et al. (2020). Identification of a Master Regulator of Differentiation in Toxoplasma. Cell. Vol.180 (2). P.359-372.e16.

Carfì Angelo, Bernabei Roberto et al. (2020). Persistent Symptoms in Patients After Acute COVID-19. JAMA. Vol. 324(6). P.603-605.

Ling Mao, Huijuan Jin, Mengdie Wang, Yu Hu et al. (2020). Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. Vol. 77(6). P.683-690.

Lehmann AA, Kirchenbaum GA, Zhang T, Reche PA, Lehmann PV. Deconvoluting the T Cell Response to SARS-CoV-2: specificity versus chance and cognate cross-reactivity. Front Immunol. (2021) 12:635942. 12:635942.

Teka I.A., Benhasan M.H., Alkershini A.A. et al. (2021) Reinfection with SARS-CoV-2: A case report from Libya. Travel Med Infect Dis. 41:102040.

Goplen N. P., Wu Y., Son Y. M., et al. (2020).Tissue-resident CD8+ T cells drive age-associated chronic lung sequelae after viral pneumonia. Sci. Immunol. 5, eabc4557



How to Cite

Makienko, N., Minukhin, V., Kolyada, T., Toryanyk, I., & Sklyar, anatoly. (2022). The main clinical and immunological aspects of post-COVID syndrome. Annals of Mechnikov’s Institute, (3), 21–27.